Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 22.9% in December

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 799,400 shares, an increase of 22.9% from the November 30th total of 650,600 shares. Approximately 4.7% of the company’s stock are sold short. Based on an average daily volume of 164,300 shares, the short-interest ratio is presently 4.9 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TELO. Geode Capital Management LLC lifted its holdings in shares of Telomir Pharmaceuticals by 259.8% in the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock worth $1,533,000 after purchasing an additional 172,382 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Telomir Pharmaceuticals during the second quarter valued at about $241,000. Suncoast Equity Management raised its holdings in shares of Telomir Pharmaceuticals by 109.9% in the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after acquiring an additional 26,803 shares during the last quarter. State Street Corp lifted its position in Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock valued at $232,000 after acquiring an additional 17,967 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC boosted its stake in Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after purchasing an additional 9,950 shares during the last quarter.

Telomir Pharmaceuticals Price Performance

Shares of NASDAQ TELO traded up $0.06 during trading on Friday, hitting $4.87. 206,793 shares of the company traded hands, compared to its average volume of 105,105. The business’s fifty day moving average is $4.60 and its 200 day moving average is $4.82. Telomir Pharmaceuticals has a fifty-two week low of $3.11 and a fifty-two week high of $20.72.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.